| |
IQVIA eCOA expert, Edward Bartels, walks through the capabilities and key features of the IQVIA eCOA platform. Watch the demo to explore functionalities from study design, eDiary and questionnaire design, and active study management. 
|
|
Today’s Big NewsOct 18, 2024 |
|
Patient perspectives, priorities, and preferences – without these criteria, designing truly patient-centric rare disease trials is impossible. Turn up the volume of the patient voice on your next study with the help of our guide. 
|
|
| By Kevin Dunleavy Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody candidate clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim. Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season. |
|
|
|
By Darren Incorvaia,Zoey Becker It’s been a whirlwind year for Joerg Moeller, M.D. After being appointed CEO of BenevolentAI in January, Moeller is now out the door of the AI drug discoverer, effective immediately. |
By Nick Paul Taylor Roche has made another MAGE-A4 program disappear, withdrawing a phase 1 trial of a T-cell bispecific prospect before a single patient was enrolled. |
Sponsored by Cryoport Systems Discover how Cryoport Systems is revolutionizing gene therapy logistics with its Elite Ultra Cold shipping system. Learn about extended hold times, enhanced security and real-time monitoring designed to protect high-value therapies in transit. |
|
Cryoport Systems' temperature-controlled supply chain solutions, including biostorage, drug labelling, kit production, cryopreservation & consulting were built with scalability in mind, Enabling The Outcome™️ for patients around the world. Learn More. .png)
|
|
By Nick Paul Taylor Supernus Pharmaceuticals has linked its mTORC1 activator to rapid improvements in adults with major depressive disorder in a small trial, pointing to one possible path forward for a candidate that is barreling toward phase 2b data in another indication. |
Sponsored by Travere Therapeutics When a specialized field of medicine has long been quiet, a buzz of breakthrough can seem like a sudden development. The reality is more nuanced. |
By James Waldron Taiwan’s REGiMMUNE and Europe-based Kiji Therapeutics are merging to create a globally minded regulatory T cell biotech that already has its sights set on an IPO. |
By Darren Incorvaia With its lead candidate in a phase 3 trial for a rare eye cancer, Aura Biosciences is looking to expand the drug into a more common disease: bladder cancer. |
By Ayla Ellison,Gabrielle Masson In this week’s episode of “The Top Line,” we catch up with three past Fierce 15 honorees to gain their insights, experiences and visions for the evolving biotech landscape. |
By Angus Liu After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. |
By Fraiser Kansteiner A dozen consumer groups and trade unions penned a letter to Lina Khan, chair of the U.S. Federal Trade Commission, urging the antitrust agency to block Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent. The call to action comes a week after Sen. Elizabeth Warren voiced similar concerns. |
By Angus Liu Eli Lilly is making a series of investments in China. Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A study suggests Leqembi's vial design could cost Medicare hundreds of millions of dollars in waste each year. And more. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “The Top Line,” we catch up with three past Fierce 15 honorees to gain their insights, experiences and visions for the evolving biotech landscape. |
|
|---|
|
|
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
